Galectin Therapeutics

11/13/2023

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023

The Investor Relations website contains information about Galectin Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.

11/03/2023

We are excited to announce we will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD) next week.

Read more: https://investor.galectintherapeutics.com/news-releases/news-release-details/galectin-therapeutics-share-five-scientific-presentations-0

11/01/2023

Nearly 2 million Americans will develop cirrhosis from fatty liver disease – and there’s still no treatment. Galectin Therapeutics CEO Joel Lewis joined Bloomberg's “The Tape” show with Paul Sweeney and Matt Miller to share how Galectin is working to change that, with a drug aimed at helping patients survive without a liver transplant.

Listen to the episode here: https://www.bloomberg.com/news/audio/2023-10-24/biotech-and-drug-development

10/26/2023

Nearly 2 million Americans will develop cirrhosis from fatty liver disease – and there’s still no treatment. Galectin Therapeutics CEO Joel Lewis joined Bloomberg’s “The Tape” show with Paul Sweeney and Matt Miller to share how Galectin is working to change that, with a drug aimed at helping patients survive without a liver transplant.

Matt Miller and Paul Sweeney focus on market coverage as Wall Street begins its day, with analysis from Bloomberg Opinion writers, Bloomberg Intelligence analysts, and influential newsmakers.

10/23/2023

Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation on Tuesday, October 24, 2023 at 11:30 AM ET.

It will be available on our website later today.

The Investor Relations website contains information about Galectin Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.

10/12/2023

Galectin is honored Dr. Carson has accepted nomination as a candidate for Galectin’s board of directors. He brings exceptional medical, scientific, and regulatory acumen and a passion for the work we are doing to develop potentially life-saving therapies.

The Investor Relations website contains information about Galectin Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.

09/22/2023

Galectin's Chief Medical Office, Dr. Pol F. Boudes, will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session of the 20th Edition of the Discovery on Target meeting on Wednesday, Sept. 27th.

09/12/2023

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held tomorrow. We are very excited to share the unique set of data we have collected with the medical, patient, and regulatory communities.

The Investor Relations website contains information about Galectin Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.

09/07/2023

Galectin Therapeutics is very excited to share the unique set of data we have collected with the medical, patient, and regulatory communities at the 9th Edition of the Paris NASH meeting today and tomorrow.

The Investor Relations website contains information about Galectin Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.

08/14/2023

“We are increasingly optimistic as we oversee and manage our adaptively designed Phase 2b/3 NAVIGATE trial for the prevention of esophageal varices in patients with NASH cirrhosis, which completed randomization of 357 patients in February 2023. To help manage NAVIGATE we have added several key staff members over the past few months in the areas of biostatistics, quality assurance, and clinical operations." Joel Lewis, CEO and President of Galectin Therapeutics

The Investor Relations website contains information about Galectin Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.

06/26/2023

"An analysis of data from 32,726 adults who participated in that study revealed that overall, NAFLD rose from 16% in 1988 to 37% in 2018, an increase of 131%."

Certain genes and metabolic disorders such as obesity, diabetes and high blood pressure may raise the risk of the most common cause of liver disease.

06/08/2023

Join us in supporting International NASH Day and making a difference for the 115 million people worldwide living with NASH cirrhosis. There is currently no treatment for NASH cirrhosis — Galectin Therapeutics wants to change that. Help us find treatment. Learn more: https://galectintherapeutics.com/